Matches in Nanopublications for { <http://www.w3.org/2000/01/rdf-schema#SENTENCE> ?p ?o ?g. }
- SENTENCE label "dexamethasone (Dex) showed stronger affinity to dexamethasone (Dex)'s theoretical (glucocorticoid) receptor with a superior docking score of −14.7 and a good binding energy value of −147.48 kcal/mol; while short hydrogen bond distances were observed in both SARS-CoV-2 main protease (Mpro) and IL-6 when compared to its theoretical (glucocorticoid) receptor." provenance.
- SENTENCE label "dexamethasone (Dex) showed stronger affinity to dexamethasone (Dex)'s theoretical (glucocorticoid) receptor with a superior docking score of −14.7 and a good binding energy value of −147.48 kcal/mol; while short hydrogen bond distances were observed in both SARS-CoV-2 main protease (Mpro) and IL-6 when compared to its theoretical (glucocorticoid) receptor." provenance.
- SENTENCE label "dexamethasone (Dex) showed stronger affinity to dexamethasone (Dex)'s theoretical (glucocorticoid) receptor with a superior docking score of −14.7 and a good binding energy value of −147.48 kcal/mol; while short hydrogen bond distances were observed in both SARS-CoV-2 main protease (Mpro) and IL-6 when compared to its theoretical (glucocorticoid) receptor." provenance.
- SENTENCE label "dexamethasone (Dex) showed stronger affinity to dexamethasone (Dex)'s theoretical (glucocorticoid) receptor with a superior docking score of −14.7 and a good binding energy value of −147.48 kcal/mol; while short hydrogen bond distances were observed in both SARS-CoV-2 main protease (Mpro) and IL-6 when compared to its theoretical (glucocorticoid) receptor." provenance.
- SENTENCE label "dexamethasone (Dex) showed stronger affinity to dexamethasone (Dex)'s theoretical (glucocorticoid) receptor with a superior docking score of −14.7 and a good binding energy value of −147.48 kcal/mol; while short hydrogen bond distances were observed in both SARS-CoV-2 main protease (Mpro) and IL-6 when compared to its theoretical (glucocorticoid) receptor." provenance.
- SENTENCE label "dexamethasone (Dex) showed stronger affinity to dexamethasone (Dex)'s theoretical (glucocorticoid) receptor with a superior docking score of −14.7 and a good binding energy value of −147.48 kcal/mol; while short hydrogen bond distances were observed in both SARS-CoV-2 main protease (Mpro) and IL-6 when compared to its theoretical (glucocorticoid) receptor." provenance.
- SENTENCE label "Results dexamethasone and 5-HT3 antagonist combination effectively reduced the incidence of PONV (3.05%, 22/721), and the patients who experienced PONV had statistically prolonged phase II recovery time as compared those who did not (P) = 0.006)." provenance.
- SENTENCE label "Results dexamethasone and 5-HT3 antagonist combination effectively reduced the incidence of PONV (3.05%, 22/721), and the patients who experienced PONV had statistically prolonged phase II recovery time as compared those who did not (P) = 0.006)." provenance.
- SENTENCE label "Results dexamethasone and 5-HT3 antagonist combination effectively reduced the incidence of PONV (3.05%, 22/721), and the patients who experienced PONV had statistically prolonged phase II recovery time as compared those who did not (P) = 0.006)." provenance.
- SENTENCE label "Results dexamethasone and 5-HT3 antagonist combination effectively reduced the incidence of PONV (3.05%, 22/721), and the patients who experienced PONV had statistically prolonged phase II recovery time as compared those who did not (P) = 0.006)." provenance.
- SENTENCE label "Results dexamethasone and 5-HT3 antagonist combination effectively reduced the incidence of PONV (3.05%, 22/721), and the patients who experienced PONV had statistically prolonged phase II recovery time as compared those who did not (P) = 0.006)." provenance.
- SENTENCE label "Results dexamethasone and 5-HT3 antagonist combination effectively reduced the incidence of PONV (3.05%, 22/721), and the patients who experienced PONV had statistically prolonged phase II recovery time as compared those who did not (P) = 0.006)." provenance.
- SENTENCE label "Interim clinical trial results suggest that the corticosteroid dexamethasone displays better 28-day survival in severe COVID-19 patients requiring ventilation or oxygen." provenance.
- SENTENCE label "Interim clinical trial results suggest that the corticosteroid dexamethasone displays better 28-day survival in severe COVID-19 patients requiring ventilation or oxygen." provenance.
- SENTENCE label "Interim clinical trial results suggest that the corticosteroid dexamethasone displays better 28-day survival in severe COVID-19 patients requiring ventilation or oxygen." provenance.
- SENTENCE label "Interim clinical trial results suggest that the corticosteroid dexamethasone displays better 28-day survival in severe COVID-19 patients requiring ventilation or oxygen." provenance.
- SENTENCE label "Interim clinical trial results suggest that the corticosteroid dexamethasone displays better 28-day survival in severe COVID-19 patients requiring ventilation or oxygen." provenance.
- SENTENCE label "Interim clinical trial results suggest that the corticosteroid dexamethasone displays better 28-day survival in severe COVID-19 patients requiring ventilation or oxygen." provenance.
- SENTENCE label "Interim clinical trial results suggest that the corticosteroid dexamethasone displays better 28-day survival in severe COVID-19 patients requiring ventilation or oxygen." provenance.
- SENTENCE label "Interim clinical trial results suggest that the corticosteroid dexamethasone displays better 28-day survival in severe COVID-19 patients requiring ventilation or oxygen." provenance.
- SENTENCE label "Interim clinical trial results suggest that the corticosteroid dexamethasone displays better 28-day survival in severe COVID-19 patients requiring ventilation or oxygen." provenance.
- SENTENCE label "Interim clinical trial results suggest that the corticosteroid dexamethasone displays better 28-day survival in severe COVID-19 patients requiring ventilation or oxygen." provenance.
- SENTENCE label "Interim clinical trial results suggest that the corticosteroid dexamethasone displays better 28-day survival in severe COVID-19 patients requiring ventilation or oxygen." provenance.
- SENTENCE label "Interim clinical trial results suggest that the corticosteroid dexamethasone displays better 28-day survival in severe COVID-19 patients requiring ventilation or oxygen." provenance.
- SENTENCE label "Interim clinical trial results suggest that the corticosteroid dexamethasone displays better 28-day survival in severe COVID-19 patients requiring ventilation or oxygen." provenance.
- SENTENCE label "Interim clinical trial results suggest that the corticosteroid dexamethasone displays better 28-day survival in severe COVID-19 patients requiring ventilation or oxygen." provenance.
- SENTENCE label "Interim clinical trial results suggest that the corticosteroid dexamethasone displays better 28-day survival in severe COVID-19 patients requiring ventilation or oxygen." provenance.
- SENTENCE label "Interim clinical trial results suggest that the corticosteroid dexamethasone displays better 28-day survival in severe COVID-19 patients requiring ventilation or oxygen." provenance.
- SENTENCE label "The fixed-effect summary OR for the association with mortality was 0.64 (95% CI, 0.50-0.82; P < .001) for dexamethasone compared with usual care or placebo (3 trials, 1282 patients, and 527 deaths), the OR was 0.69 (95% CI, 0.43-1.12; P = .13) for hydrocortisone (3 trials, 374 patients, and 94 deaths), and the OR was 0.91 (95% CI, 0.29-2.87; P = .87) for methylprednisolone (1 trial, 47 patients, and 26 deaths)." provenance.
- SENTENCE label "The fixed-effect summary OR for the association with mortality was 0.64 (95% CI, 0.50-0.82; P < .001) for dexamethasone compared with usual care or placebo (3 trials, 1282 patients, and 527 deaths), the OR was 0.69 (95% CI, 0.43-1.12; P = .13) for hydrocortisone (3 trials, 374 patients, and 94 deaths), and the OR was 0.91 (95% CI, 0.29-2.87; P = .87) for methylprednisolone (1 trial, 47 patients, and 26 deaths)." provenance.
- SENTENCE label "The fixed-effect summary OR for the association with mortality was 0.64 (95% CI, 0.50-0.82; P < .001) for dexamethasone compared with usual care or placebo (3 trials, 1282 patients, and 527 deaths), the OR was 0.69 (95% CI, 0.43-1.12; P = .13) for hydrocortisone (3 trials, 374 patients, and 94 deaths), and the OR was 0.91 (95% CI, 0.29-2.87; P = .87) for methylprednisolone (1 trial, 47 patients, and 26 deaths)." provenance.
- SENTENCE label "The fixed-effect summary OR for the association with mortality was 0.64 (95% CI, 0.50-0.82; P < .001) for dexamethasone compared with usual care or placebo (3 trials, 1282 patients, and 527 deaths), the OR was 0.69 (95% CI, 0.43-1.12; P = .13) for hydrocortisone (3 trials, 374 patients, and 94 deaths), and the OR was 0.91 (95% CI, 0.29-2.87; P = .87) for methylprednisolone (1 trial, 47 patients, and 26 deaths)." provenance.
- SENTENCE label "The fixed-effect summary OR for the association with mortality was 0.64 (95% CI, 0.50-0.82; P < .001) for dexamethasone compared with usual care or placebo (3 trials, 1282 patients, and 527 deaths), the OR was 0.69 (95% CI, 0.43-1.12; P = .13) for hydrocortisone (3 trials, 374 patients, and 94 deaths), and the OR was 0.91 (95% CI, 0.29-2.87; P = .87) for methylprednisolone (1 trial, 47 patients, and 26 deaths)." provenance.
- SENTENCE label "The fixed-effect summary OR for the association with mortality was 0.64 (95% CI, 0.50-0.82; P < .001) for dexamethasone compared with usual care or placebo (3 trials, 1282 patients, and 527 deaths), the OR was 0.69 (95% CI, 0.43-1.12; P = .13) for hydrocortisone (3 trials, 374 patients, and 94 deaths), and the OR was 0.91 (95% CI, 0.29-2.87; P = .87) for methylprednisolone (1 trial, 47 patients, and 26 deaths)." provenance.
- SENTENCE label "The fixed-effect summary OR for the association with mortality was 0.64 (95% CI, 0.50-0.82; P < .001) for dexamethasone compared with usual care or placebo (3 trials, 1282 patients, and 527 deaths), the OR was 0.69 (95% CI, 0.43-1.12; P = .13) for hydrocortisone (3 trials, 374 patients, and 94 deaths), and the OR was 0.91 (95% CI, 0.29-2.87; P = .87) for methylprednisolone (1 trial, 47 patients, and 26 deaths)." provenance.
- SENTENCE label "The fixed-effect summary OR for the association with mortality was 0.64 (95% CI, 0.50-0.82; P < .001) for dexamethasone compared with usual care or placebo (3 trials, 1282 patients, and 527 deaths), the OR was 0.69 (95% CI, 0.43-1.12; P = .13) for hydrocortisone (3 trials, 374 patients, and 94 deaths), and the OR was 0.91 (95% CI, 0.29-2.87; P = .87) for methylprednisolone (1 trial, 47 patients, and 26 deaths)." provenance.
- SENTENCE label "GL, as well as dexamethasone (DEX) dexamethasone (DEX) inhibited transactivation of nuclear factor (NF)-κ B, without inhibiting translocation of the nuclear factor (NF)-κ B p65 subunit to the nucleus." provenance.
- SENTENCE label "GL, as well as dexamethasone (DEX) dexamethasone (DEX) inhibited transactivation of nuclear factor (NF)-κ B, without inhibiting translocation of the nuclear factor (NF)-κ B p65 subunit to the nucleus." provenance.
- SENTENCE label "GL, as well as dexamethasone (DEX) dexamethasone (DEX) inhibited transactivation of nuclear factor (NF)-κ B, without inhibiting translocation of the nuclear factor (NF)-κ B p65 subunit to the nucleus." provenance.
- SENTENCE label "GL, as well as dexamethasone (DEX) dexamethasone (DEX) inhibited transactivation of nuclear factor (NF)-κ B, without inhibiting translocation of the nuclear factor (NF)-κ B p65 subunit to the nucleus." provenance.
- SENTENCE label "GL, as well as dexamethasone (DEX) dexamethasone (DEX) inhibited transactivation of nuclear factor (NF)-κ B, without inhibiting translocation of the nuclear factor (NF)-κ B p65 subunit to the nucleus." provenance.
- SENTENCE label "GL, as well as dexamethasone (DEX) dexamethasone (DEX) inhibited transactivation of nuclear factor (NF)-κ B, without inhibiting translocation of the nuclear factor (NF)-κ B p65 subunit to the nucleus." provenance.
- SENTENCE label "the corticosteroid dexamethasone would limit the production of and damaging effect of pro-inflammatory cytokines, but will also inhibit the protective function of T cells and block B cells from making antibodies, potentially leading to increased plasma viral load that will persist after a patient survives SARS." provenance.
- SENTENCE label "the corticosteroid dexamethasone would limit the production of and damaging effect of pro-inflammatory cytokines, but will also inhibit the protective function of T cells and block B cells from making antibodies, potentially leading to increased plasma viral load that will persist after a patient survives SARS." provenance.
- SENTENCE label "the corticosteroid dexamethasone would limit the production of and damaging effect of pro-inflammatory cytokines, but will also inhibit the protective function of T cells and block B cells from making antibodies, potentially leading to increased plasma viral load that will persist after a patient survives SARS." provenance.
- SENTENCE label "the corticosteroid dexamethasone would limit the production of and damaging effect of pro-inflammatory cytokines, but will also inhibit the protective function of T cells and block B cells from making antibodies, potentially leading to increased plasma viral load that will persist after a patient survives SARS." provenance.
- SENTENCE label "the corticosteroid dexamethasone would limit the production of and damaging effect of pro-inflammatory cytokines, but will also inhibit the protective function of T cells and block B cells from making antibodies, potentially leading to increased plasma viral load that will persist after a patient survives SARS." provenance.
- SENTENCE label "the corticosteroid dexamethasone would limit the production of and damaging effect of pro-inflammatory cytokines, but will also inhibit the protective function of T cells and block B cells from making antibodies, potentially leading to increased plasma viral load that will persist after a patient survives SARS." provenance.
- SENTENCE label "the corticosteroid dexamethasone would limit the production of and damaging effect of pro-inflammatory cytokines, but will also inhibit the protective function of T cells and block B cells from making antibodies, potentially leading to increased plasma viral load that will persist after a patient survives SARS." provenance.
- SENTENCE label "the corticosteroid dexamethasone would limit the production of and damaging effect of pro-inflammatory cytokines, but will also inhibit the protective function of T cells and block B cells from making antibodies, potentially leading to increased plasma viral load that will persist after a patient survives SARS." provenance.
- SENTENCE label "the corticosteroid dexamethasone would limit the production of and damaging effect of pro-inflammatory cytokines, but will also inhibit the protective function of T cells and block B cells from making antibodies, potentially leading to increased plasma viral load that will persist after a patient survives SARS." provenance.
- SENTENCE label "the corticosteroid dexamethasone would limit the production of and damaging effect of pro-inflammatory cytokines, but will also inhibit the protective function of T cells and block B cells from making antibodies, potentially leading to increased plasma viral load that will persist after a patient survives SARS." provenance.
- SENTENCE label "The efficacy of dexamethasone in preventing mortality in critical Covid-19 suggests that inflammation has a causal role in death." provenance.
- SENTENCE label "The efficacy of dexamethasone in preventing mortality in critical Covid-19 suggests that inflammation has a causal role in death." provenance.
- SENTENCE label "The efficacy of dexamethasone in preventing mortality in critical Covid-19 suggests that inflammation has a causal role in death." provenance.
- SENTENCE label "The efficacy of dexamethasone in preventing mortality in critical Covid-19 suggests that inflammation has a causal role in death." provenance.
- SENTENCE label "The efficacy of dexamethasone in preventing mortality in critical Covid-19 suggests that inflammation has a causal role in death." provenance.
- SENTENCE label "The efficacy of dexamethasone in preventing mortality in critical Covid-19 suggests that inflammation has a causal role in death." provenance.
- SENTENCE label "The efficacy of dexamethasone in preventing mortality in critical Covid-19 suggests that inflammation has a causal role in death." provenance.
- SENTENCE label "The efficacy of dexamethasone in preventing mortality in critical Covid-19 suggests that inflammation has a causal role in death." provenance.
- SENTENCE label "The efficacy of dexamethasone in preventing mortality in critical Covid-19 suggests that inflammation has a causal role in death." provenance.
- SENTENCE label "The recent announcement that RECOVERY, a randomised controlled trial comparing dexamethasone to placebo in COVID-19, was terminated early due to excess deaths in the control group further suggests patients present with secondary organising pneumonia (OP) given that corticosteroid therapy is the first-line treatment." provenance.
- SENTENCE label "The recent announcement that RECOVERY, a randomised controlled trial comparing dexamethasone to placebo in COVID-19, was terminated early due to excess deaths in the control group further suggests patients present with secondary organising pneumonia (OP) given that corticosteroid therapy is the first-line treatment." provenance.
- SENTENCE label "The recent announcement that RECOVERY, a randomised controlled trial comparing dexamethasone to placebo in COVID-19, was terminated early due to excess deaths in the control group further suggests patients present with secondary organising pneumonia (OP) given that corticosteroid therapy is the first-line treatment." provenance.
- SENTENCE label "The recent announcement that RECOVERY, a randomised controlled trial comparing dexamethasone to placebo in COVID-19, was terminated early due to excess deaths in the control group further suggests patients present with secondary organising pneumonia (OP) given that corticosteroid therapy is the first-line treatment." provenance.
- SENTENCE label "The recent announcement that RECOVERY, a randomised controlled trial comparing dexamethasone to placebo in COVID-19, was terminated early due to excess deaths in the control group further suggests patients present with secondary organising pneumonia (OP) given that corticosteroid therapy is the first-line treatment." provenance.
- SENTENCE label "The recent announcement that RECOVERY, a randomised controlled trial comparing dexamethasone to placebo in COVID-19, was terminated early due to excess deaths in the control group further suggests patients present with secondary organising pneumonia (OP) given that corticosteroid therapy is the first-line treatment." provenance.
- SENTENCE label "The recent announcement that RECOVERY, a randomised controlled trial comparing dexamethasone to placebo in COVID-19, was terminated early due to excess deaths in the control group further suggests patients present with secondary organising pneumonia (OP) given that corticosteroid therapy is the first-line treatment." provenance.
- SENTENCE label "The recent announcement that RECOVERY, a randomised controlled trial comparing dexamethasone to placebo in COVID-19, was terminated early due to excess deaths in the control group further suggests patients present with secondary organising pneumonia (OP) given that corticosteroid therapy is the first-line treatment." provenance.
- SENTENCE label "The recent announcement that RECOVERY, a randomised controlled trial comparing dexamethasone to placebo in COVID-19, was terminated early due to excess deaths in the control group further suggests patients present with secondary organising pneumonia (OP) given that corticosteroid therapy is the first-line treatment." provenance.
- SENTENCE label "The recent announcement that RECOVERY, a randomised controlled trial comparing dexamethasone to placebo in COVID-19, was terminated early due to excess deaths in the control group further suggests patients present with secondary organising pneumonia (OP) given that corticosteroid therapy is the first-line treatment." provenance.
- SENTENCE label "The recent announcement that RECOVERY, a randomised controlled trial comparing dexamethasone to placebo in COVID-19, was terminated early due to excess deaths in the control group further suggests patients present with secondary organising pneumonia (OP) given that corticosteroid therapy is the first-line treatment." provenance.
- SENTENCE label "The recent announcement that RECOVERY, a randomised controlled trial comparing dexamethasone to placebo in COVID-19, was terminated early due to excess deaths in the control group further suggests patients present with secondary organising pneumonia (OP) given that corticosteroid therapy is the first-line treatment." provenance.
- SENTENCE label "The recent announcement that RECOVERY, a randomised controlled trial comparing dexamethasone to placebo in COVID-19, was terminated early due to excess deaths in the control group further suggests patients present with secondary organising pneumonia (OP) given that corticosteroid therapy is the first-line treatment." provenance.
- SENTENCE label "The recent announcement that RECOVERY, a randomised controlled trial comparing dexamethasone to placebo in COVID-19, was terminated early due to excess deaths in the control group further suggests patients present with secondary organising pneumonia (OP) given that corticosteroid therapy is the first-line treatment." provenance.
- SENTENCE label "The recent announcement that RECOVERY, a randomised controlled trial comparing dexamethasone to placebo in COVID-19, was terminated early due to excess deaths in the control group further suggests patients present with secondary organising pneumonia (OP) given that corticosteroid therapy is the first-line treatment." provenance.
- SENTENCE label "The recent announcement that RECOVERY, a randomised controlled trial comparing dexamethasone to placebo in COVID-19, was terminated early due to excess deaths in the control group further suggests patients present with secondary organising pneumonia (OP) given that corticosteroid therapy is the first-line treatment." provenance.
- SENTENCE label "The recent announcement that RECOVERY, a randomised controlled trial comparing dexamethasone to placebo in COVID-19, was terminated early due to excess deaths in the control group further suggests patients present with secondary organising pneumonia (OP) given that corticosteroid therapy is the first-line treatment." provenance.
- SENTENCE label "The recent announcement that RECOVERY, a randomised controlled trial comparing dexamethasone to placebo in COVID-19, was terminated early due to excess deaths in the control group further suggests patients present with secondary organising pneumonia (OP) given that corticosteroid therapy is the first-line treatment." provenance.
- SENTENCE label "The recent announcement that RECOVERY, a randomised controlled trial comparing dexamethasone to placebo in COVID-19, was terminated early due to excess deaths in the control group further suggests patients present with secondary organising pneumonia (OP) given that corticosteroid therapy is the first-line treatment." provenance.
- SENTENCE label "The recent announcement that RECOVERY, a randomised controlled trial comparing dexamethasone to placebo in COVID-19, was terminated early due to excess deaths in the control group further suggests patients present with secondary organising pneumonia (OP) given that corticosteroid therapy is the first-line treatment." provenance.
- SENTENCE label "The recent announcement that RECOVERY, a randomised controlled trial comparing dexamethasone to placebo in COVID-19, was terminated early due to excess deaths in the control group further suggests patients present with secondary organising pneumonia (OP) given that corticosteroid therapy is the first-line treatment." provenance.
- SENTENCE label "The recent announcement that RECOVERY, a randomised controlled trial comparing dexamethasone to placebo in COVID-19, was terminated early due to excess deaths in the control group further suggests patients present with secondary organising pneumonia (OP) given that corticosteroid therapy is the first-line treatment." provenance.
- SENTENCE label "The recent announcement that RECOVERY, a randomised controlled trial comparing dexamethasone to placebo in COVID-19, was terminated early due to excess deaths in the control group further suggests patients present with secondary organising pneumonia (OP) given that corticosteroid therapy is the first-line treatment." provenance.
- SENTENCE label "The recent announcement that RECOVERY, a randomised controlled trial comparing dexamethasone to placebo in COVID-19, was terminated early due to excess deaths in the control group further suggests patients present with secondary organising pneumonia (OP) given that corticosteroid therapy is the first-line treatment." provenance.
- SENTENCE label "The recent announcement that RECOVERY, a randomised controlled trial comparing dexamethasone to placebo in COVID-19, was terminated early due to excess deaths in the control group further suggests patients present with secondary organising pneumonia (OP) given that corticosteroid therapy is the first-line treatment." provenance.
- SENTENCE label "The recent announcement that RECOVERY, a randomised controlled trial comparing dexamethasone to placebo in COVID-19, was terminated early due to excess deaths in the control group further suggests patients present with secondary organising pneumonia (OP) given that corticosteroid therapy is the first-line treatment." provenance.
- SENTENCE label "The recent announcement that RECOVERY, a randomised controlled trial comparing dexamethasone to placebo in COVID-19, was terminated early due to excess deaths in the control group further suggests patients present with secondary organising pneumonia (OP) given that corticosteroid therapy is the first-line treatment." provenance.
- SENTENCE label "The recent announcement that RECOVERY, a randomised controlled trial comparing dexamethasone to placebo in COVID-19, was terminated early due to excess deaths in the control group further suggests patients present with secondary organising pneumonia (OP) given that corticosteroid therapy is the first-line treatment." provenance.
- SENTENCE label "The recent announcement that RECOVERY, a randomised controlled trial comparing dexamethasone to placebo in COVID-19, was terminated early due to excess deaths in the control group further suggests patients present with secondary organising pneumonia (OP) given that corticosteroid therapy is the first-line treatment." provenance.
- SENTENCE label "The recent announcement that RECOVERY, a randomised controlled trial comparing dexamethasone to placebo in COVID-19, was terminated early due to excess deaths in the control group further suggests patients present with secondary organising pneumonia (OP) given that corticosteroid therapy is the first-line treatment." provenance.
- SENTENCE label "The recent announcement that RECOVERY, a randomised controlled trial comparing dexamethasone to placebo in COVID-19, was terminated early due to excess deaths in the control group further suggests patients present with secondary organising pneumonia (OP) given that corticosteroid therapy is the first-line treatment." provenance.
- SENTENCE label "The recent announcement that RECOVERY, a randomised controlled trial comparing dexamethasone to placebo in COVID-19, was terminated early due to excess deaths in the control group further suggests patients present with secondary organising pneumonia (OP) given that corticosteroid therapy is the first-line treatment." provenance.
- SENTENCE label "The recent announcement that RECOVERY, a randomised controlled trial comparing dexamethasone to placebo in COVID-19, was terminated early due to excess deaths in the control group further suggests patients present with secondary organising pneumonia (OP) given that corticosteroid therapy is the first-line treatment." provenance.
- SENTENCE label "The recent announcement that RECOVERY, a randomised controlled trial comparing dexamethasone to placebo in COVID-19, was terminated early due to excess deaths in the control group further suggests patients present with secondary organising pneumonia (OP) given that corticosteroid therapy is the first-line treatment." provenance.
- SENTENCE label "The recent announcement that RECOVERY, a randomised controlled trial comparing dexamethasone to placebo in COVID-19, was terminated early due to excess deaths in the control group further suggests patients present with secondary organising pneumonia (OP) given that corticosteroid therapy is the first-line treatment." provenance.
- SENTENCE label "The recent announcement that RECOVERY, a randomised controlled trial comparing dexamethasone to placebo in COVID-19, was terminated early due to excess deaths in the control group further suggests patients present with secondary organising pneumonia (OP) given that corticosteroid therapy is the first-line treatment." provenance.
- SENTENCE label "The recent announcement that RECOVERY, a randomised controlled trial comparing dexamethasone to placebo in COVID-19, was terminated early due to excess deaths in the control group further suggests patients present with secondary organising pneumonia (OP) given that corticosteroid therapy is the first-line treatment." provenance.
- SENTENCE label "The recent announcement that RECOVERY, a randomised controlled trial comparing dexamethasone to placebo in COVID-19, was terminated early due to excess deaths in the control group further suggests patients present with secondary organising pneumonia (OP) given that corticosteroid therapy is the first-line treatment." provenance.
- SENTENCE label "The recent announcement that RECOVERY, a randomised controlled trial comparing dexamethasone to placebo in COVID-19, was terminated early due to excess deaths in the control group further suggests patients present with secondary organising pneumonia (OP) given that corticosteroid therapy is the first-line treatment." provenance.